Dr Reddy’s permanently restrained by Delhi HC from commercially launching any product consisting of 'Olaparib'
The Delhi High Court has issued a permanent injunction against Dr. Reddy’s Laboratories Limited, restraining it from commercially launching any product containing 'Olaparib', Olaparib API, or any related product. This order came in response to an application filed by Kudos Pharmaceuticals Limited, Astrazeneca AB, and Astrazeneca Pharma India Ltd., alleging patent infringement by Dr. Reddy’s.
For more news & updates, check out the link given below:
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd